Work

The Role of Glial Glutamate Transporter Glt-1 Over-expression in Mitigating Visceral Nociception

Year: 2010
Type: article
Abstract: Visceral pain is the most common reason forphysician visits in US. However, the etiology of visceral hypersensitivity is not clear. Neither is the effective therapy available to relief visceral pain. Glutamate is the major excitatory neurotransmitter and mediates aspects of visceral hypersensitivity. Rapid removal of glutamate from synapse is predominantly mediated by glial glutamate transporter-1 (GLT-1), thus terminating the glutamate stimulation. GLT-1 is found down-regulated in the neuropathic injury model and the artificial induction of GLT-1 attenuates neuropathic pain. In this dissertation, the role of GLT-1 induction in visceral nociception is investigated. Genetic and pharmacological approaches were utilized to establish GLT-1 induction. In the transgenic mice model, GLT-1 transgene was driven by glial fibrillary acidic protein (GFAP) and over-expressed in astrocyte cells in central nervous system. In the pharmacological model, expression of GLT-1 was enhanced by intraperitoneal administration of ceftriaxone (CTX). Transgenic animals overexpressing GLT-1 significantly reduced visceral nociceptive responses. In consistent, one week administration of ceftriaxone reduced the visceromotor response (VMR) to colorectal distention (CRD). In addition, this inhibition of visceral nociception could be blocked by systematic treatment with dihydrokainate (DHK), a selective GLT-1 inhibitor. This data indicates that enhanced glutamate reuptake attenuates colorectal distention-induced visceral nociception.Further study showed that intrathecal delivery of GLT-1 antagonist DHK to the lumbar spinal cord dose-dependently reversed CTX-blunted visceral nociceptive response, whereas intracisternal delivery of DHK failed to produce visceral anti-nociceptive effects, suggesting a role of spinally located glutamate transporter GLT-1 in visceral nociception. In addition, one-week CTX treatment exhibited no effect on somatic sensory and motor function. This data indicated that GLT-1 upregulation by CTX treatment mitigates visceral nociception through spinal mechanisms. The role of GLT-1 in animal models of colitis was then investigated. One week CTX treatment upregulated the expression of GLT-1 and reversed the TNBS-induced visceral hypersensitivity. In addition, CTX treatment one week after the onset of DSS-induced visceral inflammation could also attenuate the visceral nociceptive response, suggesting a potential therapeutic effect of CTX. Further experiment revealed that CTX treatment reduced inflammation in the TNBS-induced colitis, but not in DSS model. Cephalothin, another antibiotic lacking GLT-1 induction ability, demonstrated the efficiency to inhibit inflammation but failed to block visceral hypersensitivity, suggesting that GLT-1 over-expression mitigates visceral inflammatory nociception. Taken together, these studies indicated that GLT-1 over-expression is a novel and effective method to attenuate visceral nociception.
Author: Yuan Lin
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W2236417794
FWCI:
Cites: 255
Cited by:
Related to: 9